NCT02955069 - Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

August 10, 2018

Study Completion Date

May 13, 2020

Conditions

Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic OriginPoorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions

DRUG

PDR001

PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.

Trial Locations (35)

2065

Novartis Investigative Site, St Leonards

3000

Novartis Investigative Site, Leuven

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

13273

Novartis Investigative Site, Marseille

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

31054

Novartis Investigative Site, Toulouse

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

35039

Novartis Investigative Site, Marburg

40138

Novartis Investigative Site, Bologna

45147

Novartis Investigative Site, Essen

47014

Novartis Investigative Site, Meldola

55131

Novartis Investigative Site, Mainz

55905

Mayo Clinic - Rochester, Rochester

69437

Novartis Investigative Site, Lyon

77030

University of TX MD Anderson Cancer Center, Houston

80131

Novartis Investigative Site, Napoli

80218

Rocky Mountain Cancer Centers SC-2, Denver

91010

City of Hope National Medical Center, Duarte

91054

Novartis Investigative Site, Erlangen

A-1090

Novartis Investigative Site, Vienna

BE-B-1200

Novartis Investigative Site, Brussels

M4N 3M5

Novartis Investigative Site, Toronto

H3T 1E2

Novartis Investigative Site, Montreal

00189

Novartis Investigative Site, Roma

464 8681

Novartis Investigative Site, Nagoya

277 8577

Novartis Investigative Site, Kashiwa

812-8582

Novartis Investigative Site, Fukuoka

104 0045

Novartis Investigative Site, Chuo Ku

1066 CX

Novartis Investigative Site, Amsterdam

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

NW3 2PR

Novartis Investigative Site, London